Show Summary Details
- Preface
- Contributors
- 1 The human γ-aminobutyric acid transporter GAT-2: from cloning to high throughput screening
- 2 Low throughput preclinical models for headache*
- 3 Human models: screening models
- 4 Stricter success criteria, qualitative and quantitative end-points: acute versus prevention trials
- 5 Health-related quality of life and similar end-points
- 6 Clinically relevant designs and outcome measures for acute migraine trials
- 7 Effectiveness of different steroid dosage in Tolosa–Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification
- 8 Discussion summary: Trials methodology
- 9 Inducible nitric oxide synthase and development of new migraine treatments
- 10 Mechanisms of cortical spreading depression as targets for migraine therapy
- 11 Tonabersat
- 12 Discussion summary: Nitric oxide and spreading depression modulators
- 13 Calcitonin gene-related peptide: relevance for migraine
- 14 New 5-hydroxytryptamine-related drug targets
- 15 Effect of two novel calcitonin gene-related peptide-binding compounds in a closed cranial window rat model
- 16 Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment
- 17 Discussion summary: Calcitonin gene-related peptide and 5-hydroxytryptamine modulators
- 18 Migraine: from genes to pathophysiology – transgenic mouse models of migraine
- 19 KATP channels and migraine
- 20 Antiepileptic drugs and migraine
- 21 Discussion summary: Ion channel modulators and antiepileptics
- 22 Innovative drug development for headache disorders: glutamate
- 23 The modulation of TRPV1 channels by cannabinoid1 receptors
- 24 Future targets for headache therapy: prostanoids
- 25 Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat
- Index
(p. 143) KATP channels and migraine
(p. 143)
KATP channels and migraine
- Chapter:
- (p. 143) KATP channels and migraine
- Author(s):
Inger Jansen-Olesen
and Kenneth Beri Ploug
- DOI:
- 10.1093/med/9780199552764.003.0019
Chapter 19 discusses Adenosine 5´-triphosphate (ATP) sensitive K+(KATP) channels, and their relation to migraine.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Preface
- Contributors
- 1 The human γ-aminobutyric acid transporter GAT-2: from cloning to high throughput screening
- 2 Low throughput preclinical models for headache*
- 3 Human models: screening models
- 4 Stricter success criteria, qualitative and quantitative end-points: acute versus prevention trials
- 5 Health-related quality of life and similar end-points
- 6 Clinically relevant designs and outcome measures for acute migraine trials
- 7 Effectiveness of different steroid dosage in Tolosa–Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification
- 8 Discussion summary: Trials methodology
- 9 Inducible nitric oxide synthase and development of new migraine treatments
- 10 Mechanisms of cortical spreading depression as targets for migraine therapy
- 11 Tonabersat
- 12 Discussion summary: Nitric oxide and spreading depression modulators
- 13 Calcitonin gene-related peptide: relevance for migraine
- 14 New 5-hydroxytryptamine-related drug targets
- 15 Effect of two novel calcitonin gene-related peptide-binding compounds in a closed cranial window rat model
- 16 Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment
- 17 Discussion summary: Calcitonin gene-related peptide and 5-hydroxytryptamine modulators
- 18 Migraine: from genes to pathophysiology – transgenic mouse models of migraine
- 19 KATP channels and migraine
- 20 Antiepileptic drugs and migraine
- 21 Discussion summary: Ion channel modulators and antiepileptics
- 22 Innovative drug development for headache disorders: glutamate
- 23 The modulation of TRPV1 channels by cannabinoid1 receptors
- 24 Future targets for headache therapy: prostanoids
- 25 Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat
- Index